Title :

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients

Author(s) :

Zufferey, Paul Jacques [Auteur]
Dupont, Annabelle [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Lanoiselée, Julien [Auteur]
Bauters, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Poissy, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
GOUTAY, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Jean, Laurent [Auteur]
Agence française de développement [AFD]
Caplan, Morgan [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Levy, Lionel [Auteur]
Susen, Sophie [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Delavenne, Xavier [Auteur]
Biologie Intégrative du Tissu Osseux [LBTO]

Journal title :

Thrombosis Research

Volume number :

205

Pages :

120-127

Publisher :

Elsevier

Publication date :

2021-09

ISSN :

0049-3848

English keyword(s) :

enoxaparin COVID-19 pharmacokinetics Critical Care
enoxaparin
COVID-19
pharmacokinetics
Critical Care

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Cardiologie et système cardiovasculaire

English abstract : [en]

Purpose In intensive-care unit (ICU) patients, pathophysiological changes may affect the pharmacokinetics of enoxaparin and result in underdosing. The aim of this study was to develop a pharmacokinetic model of enoxaparin ...
Show more >Purpose In intensive-care unit (ICU) patients, pathophysiological changes may affect the pharmacokinetics of enoxaparin and result in underdosing. The aim of this study was to develop a pharmacokinetic model of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-19 ICU-patients. Methods Anti-Xa activities from consecutive ICU-patients with laboratory-confirmed SARS-CoV-2 infection treated by enoxaparin for the prevention or the treatment of venous thrombosis were used to develop a population pharmacokinetic model using non-linear mixed effects techniques. Monte Carlo simulations were then performed to predict enoxaparin exposure at steady-state after three days of administration. Results A total of 391 anti-Xa samples were measured in 95 patients. A one-compartment model with first-order kinetics best fitted the data. The covariate analysis showed that enoxaparin clearance was related to renal function estimated by the CKD-EPI formula and volume of distribution to actual body weight. Simulations indicated that compared to enoxaparin 40 mg qd in medical patients, enoxaparin 30 mg bid in ICU COVID-19 patients achieved similar 24- hour area under the plasma concentration–time curve values while therapeutic dose anticoagulation increased median exposure by 2.8 fold. Conclusion To achieve exposures similar as those expected in non-ICU non-COVID-19 patients a 50 percent increase in dose administration is required.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011
• Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576

Research team(s) :

Glycobiology in fungal Pathogenesis and Clinical Applications

Submission date :

2024-03-27T15:27:55Z